Immediate Impact

54 standout
Sub-graph 1 of 23

Citing Papers

Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
2024 Standout
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
2023 Standout
1 intermediate paper

Works of Alan Clucas being referenced

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
2019

Author Peers

Author Last Decade Papers Cites
Alan Clucas 365 26 10 136 73 13 466
Maritza A. Middelkamp‐Hup 434 41 165 70 15 563
J-H. Saurat 290 75 2 125 54 16 484
Mingeum Jeong 287 16 4 169 87 10 412
Dae Cho 265 32 5 68 51 9 419
N.J. Fincham 164 23 7 63 83 18 502
M Mattii 347 37 4 65 93 13 517
Bridget Kaufman 351 25 21 171 77 15 424
Urs Kerkmann 347 62 2 110 66 23 521
Krisztiná Szegedi 302 42 4 194 132 9 473
James Tarbox 282 7 9 181 77 20 436

All Works

Loading papers...

Rankless by CCL
2026